Dr. Rosenberg Discusses the Importance of Clinical Trials in Bladder Cancer

Jonathan E. Rosenberg, MD
Published: Wednesday, Sep 06, 2017



Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of referring patients to clinical trials in bladder cancer.

There is a long history of failed adjuvant clinical trials in bladder cancer due to poor accrual, says Rosenberg. He says that is important for treating physicians to recommend patients for these trials in order to test novel adjuvant therapies.

Adjuvant immunotherapy trials are showing greater success in accrual though, Rosenberg adds.
 
SELECTED
LANGUAGE


Jonathan E. Rosenberg, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of referring patients to clinical trials in bladder cancer.

There is a long history of failed adjuvant clinical trials in bladder cancer due to poor accrual, says Rosenberg. He says that is important for treating physicians to recommend patients for these trials in order to test novel adjuvant therapies.

Adjuvant immunotherapy trials are showing greater success in accrual though, Rosenberg adds.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x